LAM Therapeutics Announces Progress of its Clinical Portfolio with FDA Clearance of New Trial in Leukemia and Advancement of Clinical Trial in Lymphoma

Return to News >

Collaboration announced for combination study with atezolizumab in non-Hodgkin B-cell lymphoma

GUILFORD, Conn.—Nov. 30, 2017– LAM Therapeutics (LAM), a 4Catalyzer company, advanced its clinical portfolio with the U.S. Food and Drug Administration (FDA) clearance of LAM’s Investigational New Drug (IND) application for LAM-003 in leukemia patients. LAM-002 has transitioned into Phase 2 […]

2017-12-20T10:54:35+00:00 November 30th, 2017|Categories: News|

LAM Therapeutics Announces Close of $58M Series C Financing and New Clinical Program in Cancer

Return to News >

Strategy and Portfolio Update

GUILFORD, Conn., March 30, 2017 – LAM Therapeutics, a 4Catalyzer company that develops drugs for cancer and rare diseases, announced that it has closed $58M in Series C financing. 4Catalyzer is Connecticut’s premier biotechnology incubator and has raised over a quarter billion dollars to support its current class […]

2017-12-20T10:57:29+00:00 March 30th, 2017|Categories: News|

LAM Therapeutics Closes $40M in Financing and Announces Two Clinical-Stage Programs in Rare Diseases and Cancer

Return to News >

Bringing the total raised for the current class of 4Catalyzer companies to a quarter-billion dollars

GUILFORD, Conn. –Feb. 2, 2016– LAM Therapeutics closed a $40 million financing to accelerate the development of therapeutics for the treatment of rare diseases and cancer. LAM Therapeutics is a 4Catalyzer company. 4Catalyzer is Connecticut’s premier biotechnology […]

2017-12-20T10:57:06+00:00 February 3rd, 2016|Categories: News|

LAM Therapeutics launches operations to develop drugs for rare lung disease, Lymphangioleiomyomatosis (LAM)

Return to News >

Company is first to focus on developing drugs for Lymphangioleiomyomatosis

Guilford, CT – June 6, 2013 – LAM Therapeutics, the first biopharmaceutical company dedicated to identifying and developing drugs for the treatment of Lymphangioleiomyomatosis (LAM), announced today that it has closed a Series A financing with private investors to launch operations. Proceeds […]

2017-12-20T10:56:35+00:00 June 6th, 2013|Categories: News|